IRONMAN试验:静脉铁剂治疗心衰患者住院与死亡原因裁定分析
IRONMAN随机试验比较静脉铁剂FDI与常规治疗在心衰合并缺铁患者中的效果,中位随访2.7年。FDI组非计划住院减少(RR 0.83),心衰和呼吸疾病住院亦减少,心血管与非心血管住院降幅相似;心血管及全因死亡模式两组相似。
要点
- FDI组非计划住院率显著低于常规治疗(RR 0.83,95%CI 0.71-0.97)
- 心衰住院RR 0.78,呼吸疾病住院RR 0.70,均见下降
- 心血管与非心血管住院降幅相似,死亡模式无差异
核心结论
- 静脉铁剂FDI对心血管和非心血管住院的降低幅度相似,提示纠正缺铁可能增强心衰患者对多种住院病因的抵抗或恢复力。
研究设计与样本
- IRONMAN随机试验,比较静脉羧基麦芽糖铁(FDI,n=568)与常规治疗(n=569)。
- 入选心衰、左室射血分数≤45%、转铁蛋白饱和度<20%或血清铁蛋白<100 μg/L的患者,中位随访2.7年(Q1-Q3:1.8-3.6年)。
- 由委员会裁定非计划住院和死亡的主因及促因。
主要发现
- FDI组非计划住院少于常规治疗(RR 0.83;95%CI 0.71-0.97;P=0.02)。
- 心血管住院RR 0.83(95%CI 0.69-1.01),非心血管住院RR 0.83(95%CI 0.67-1.03)。
- 心衰住院RR 0.78(95%CI 0.60-1.00),呼吸疾病住院RR 0.70(95%CI 0.53-0.97),感染住院RR 0.82(95%CI 0.66-1.03)。
- 心衰是26%住院的主因,另12%住院中为促因或并发症;感染导致或促发38%住院,其中心衰住院的27%。
- FDI组与常规治疗组的心血管死亡和全因死亡模式相似。
临床怎么用
- 对心衰合并缺铁(LVEF≤45%,TSAT<20%或铁蛋白<100 μg/L)患者,可考虑静脉FDI以减少非计划住院。
- FDI可能同时减少心衰和呼吸疾病相关住院,不增加死亡风险信号。
局限性
- 住院原因裁定为探索性分析,部分事件RR的95%CI跨越1(如心血管、非心血管、心衰、感染住院)。
- 原文摘要未报告样本量计算、具体P值(除非计划住院外)及亚组分析细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with heart failure and iron deficiency have diverse causes for hospitalization and death that might be affected by iron repletion. OBJECTIVES: The purpose of this study was to explore causes of hospitalizations and deaths in a randomized trial (IRONMAN) of heart failure comparing intravenous ferric derisomaltose (FDI) (n = 568) and usual care (n = 569). METHODS: Patients with heart failure, left ventricular ejection fraction ≤45%, and either transferrin saturation <20% or serum ferritin <100 μg/L were enrolled. Median follow-up was 2.7 years (Q1-Q3: 1.8-3.6 years). A committee adjudicated the main and contributory causes of unplanned hospitalizations and deaths. RRs (rate ratios) for selected recurrent events with 95% CIs are also reported. RESULTS: Compared with usual care, patients randomized to FDI had fewer unplanned hospitalizations (RR: 0.83; 95% CI: 0.71-0.97; P = 0.02), with similar reductions in cardiovascular (RR: 0.83; 95% CI: 0.69-1.01) and noncardiovascular (RR: 0.83; 95% CI: 0.67-1.03) hospitalizations, as well as hospitalizations for heart failure (RR: 0.78; 95% CI: 0.60-1.00), respiratory disease (RR: 0.70; 95% CI: 0.53-0.97), or infection (RR: 0.82; 95% CI: 0.66-1.03). Heart failure was the main cause for 26% of hospitalizations and contributed to or complicated a further 12%. Infection caused or contributed to 38% of all hospitalizations, including 27% of heart failure hospitalizations. Patterns of cardiovascular and all-cause mortality were similar for patients assigned to FDI or usual care. CONCLUSIONS: In IRONMAN, FDI exerted similar reductions in cardiovascular and noncardiovascular hospitalizations, suggesting that correcting iron deficiency might increase resistance or resilience to a broad range of problems that cause hospitalizations in patients with heart failure. (Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency; NCT02642562).
引用
- Cleland, Pellicori, Graham, et al. Adjudication of Hospitalizations and Deaths in the IRONMAN Trial of Intravenous Iron for Heart Failure. J Am Coll Cardiol. 2024. PMID: 39443013. doi:10.1016/j.jacc.2024.08.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。